SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001104659-22-070546
Filing Date
2022-06-13
Accepted
2022-06-13 16:24:13
Documents
1
Group Members
FORESITE CAPITAL MANAGEMENT V, LLCFORESITE CAPITAL OPPORTUNITY FUND V, L.P.FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLCJAMES B. TANANBAUM

Document Format Files

Seq Description Document Type Size
1 SC 13D/A tm2218245d1_sc13da.htm SC 13D/A 94516
  Complete submission text file 0001104659-22-070546.txt   96224
Mailing Address 314 MAIN STREET, SUITE 04-200 CAMBRIDGE MA 02142
Business Address 314 MAIN STREET, SUITE 04-200 CAMBRIDGE MA 02142 (857) 400-9491
Theseus Pharmaceuticals, Inc. (Subject) CIK: 0001745020 (see all company filings)

IRS No.: 830712806 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-92944 | Film No.: 221011912
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences

Mailing Address 600 MONTGOMERY STREET, SUITE 4500 SAN FRANCISCO CA 94111
Business Address 600 MONTGOMERY STREET, SUITE 4500 SAN FRANCISCO CA 94111 415-877-4887
Foresite Capital Fund V, L.P. (Filed by) CIK: 0001792204 (see all company filings)

IRS No.: 843449937 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A